

May 22, 2025-

Expanded Access Policy for KUS121

Kyoto Drug Discovery & Development Co., Ltd. (KDDD) is currently conducting clinical trials to evaluate the safety and efficacy of KUS121, an investigational drug for the treatment of retinal artery occlusion (RAO). At this time, KDDD does not offer an expanded access program for KUS121 outside of these ongoing clinical trials.

We understand that patients and physicians may be interested in accessing investigational treatments prior to regulatory approval. However, due to the early stage of development and limited supply of KUS121, we are unable to provide the investigational product through expanded access at this time.

If KDDD establishes an expanded access program in the future, we will update this page with detailed information, including eligibility criteria, application procedures, and the typical time frame for response to such requests.

For questions regarding the clinical development of KUS121 or future availability of expanded access, please contact:

Email: clinical@kyoto-drug.com

Phone: +81-6-7777-1103

Mailing Address: Kyoto Drug Discovery & Development Co., Ltd.

8F, DP Square Sakaisuji Honmachi 1-6-9, Awaji-Machi

Chuo-ku, Osaka, 541-0047 JAPAN